Short Communication
The impact of comorbidities and sociodemographic predictors on pneumococcal vaccination coverage in adults with coronary heart disease
Published Online:19 Dec 2023https://doi.org/10.2217/fca-2023-0095
Abstract
Aim: Coronary heart disease (CHD) increases the risk of adverse outcomes from invasive pneumococcal disease. Methods: Using the 2020 and 2021 data from the national health interview survey, we identified adults with CHD. Chi-square analysis and logistic regression were used to examine factors that influence vaccination status. Results: There were 2675 participants aged 41 and above with CHD. Participants were predominantly white people (82.5%) and males (60.1%). The odds of receiving the pneumococcal vaccine increased with stepwise increase in comorbidities from 1 to 2 and from 2 to 3. Among individuals with ≥2 comorbidities, black people were less likely to be vaccinated compared with white people. Conclusion: Pneumococcal vaccine uptake among adults with CHD is determined by cumulative comorbidities and ethnicity.
Keywords:
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1. . The association between pneumococcal pneumonia and acute cardiac events. Clin. Infect. Dis. 45(2), 158–165 (2007). •• Shows possible cardioprotective effect of the pneumococcal vaccine.
- 2. Major adverse cardiovascular events during invasive pneumococcal disease are serotype dependent. Clin. Infect. Dis. 72(11), e711–e719 (2021).
- 3. Pneumococcal vaccination in adults at very high risk or with established cardiovascular disease: systematic review and meta-analysis. Eur. Heart J. Qual. Care Clin. Outcomes 7(1), 97–106 (2021).
- 4. . Invasive pneumococcal and meningococcal disease. Infect. Dis. Clin. North Am. 33(4), 1125–1141 (2019).
- 5. Effect of pneumococcal vaccine on mortality and cardiovascular outcomes: a systematic review and meta-analysis. J. Clin. Med. 11(13), 10–11 (2022). •• Shows possible cardioprotective effect of the pneumococcal vaccine.
- 6. . The health belief model predicts vaccination intentions against COVID-19: a survey experiment approach. Appl. Psychol. Health Well Being 13(2), 469–484 (2021).
- 7. Socioeconomic status and other related factors of seasonal influenza vaccination in the South Korean adult population based on a nationwide cross-sectional study. PLOS ONE 10(2), e0117305 (2015).
- 8. . Vaccine hesitancy. Vaccine 33, D66–D71 (2015).
- 9. . Causes of vaccine hesitancy in adults for the influenza and COVID-19 vaccines: a systematic literature review. Vaccines (Basel) 10(9), 1518 (2022).
- 10. Extent of and reasons for vaccine hesitancy in adults at high-risk for pneumococcal disease. Am. J. Health Prom. 35(7), 908–916 (2021).
- 11. . Understanding factors associated with vaccine uptake and vaccine hesitancy in patients with rheumatoid arthritis: a scoping literature review. Clin. Rheumatol. 40(2), 477–489 (2021).
- 12. . Factors associated with early receipt of COVID-19 vaccination and adherence to second dose in the Veterans Affairs healthcare system. PLOS ONE 16(12), e0259696 (2021). • Shows the influence of age and comorbidities on pneumococcal vaccine uptake.
- 13. . Pneumococcal vaccination uptake among patients aged 65 years or over in Australian general practice. Hum. Vaccin. Immunother. 16(4), 965–971 (2020).
- 14. The Center for Disease Control and Prevention, USA. ‘NHIS - About the National Health Interview Survey’ (2022). www.cdc.gov/nchs/nhis/about_nhis.htm
- 15. . Relation between age and coronary heart disease (CHD) risk in Asian Indian patients with diabetes: a cross-sectional and prospective cohort study. Diabetes Res. Clin. Pract. 81(2), 243–249 (2008).
- 16. Diseases NC for I and R. ‘Pneumococcal Vaccination: Who and When to Vaccinate | CDC’ (2022). www.cdc.gov/vaccines/vpd/pneumo/hcp/who-when-to-vaccinate.html
- 17. The Center for Disease Control and Prevention, USA. ‘Vaccination Coverage among Adults in the United States, National Health Interview Survey, 2019–2020 | CDC’. 9, (2022). www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/pubs-resources/vaccination-coverage-adults-2019-2020.html
- 18. . Pneumococcal vaccination coverage among adults newly diagnosed with underlying medical conditions and regional variation in the US. Vaccine 40(33), 4856–4863 (2022).
- 19. . Pneumococcal vaccination coverages by age, sex and specific underlying risk conditions among middle-aged and older adults in Catalonia, Spain, 2017. Eurosurveillance 24(29), (2019). • Shows the influence of age and comorbidities on pneumococcal vaccine uptake.
- 20. Racial disparities in adult pneumococcal vaccination indications and pneumococcal hospitalizations in the US. J. Natl Med. Assoc. 111(5), 540–545 (2019).
- 21. . What Is a “Racial Health Disparity”? Five analytic traditions. J. Health Polit. Policy Law 47(2), 131–158 (2022).
- 22. . Racial and ethnic disparities in health insurance coverage: dynamics of gaining and losing coverage over the life-course. Popul. Res. Policy Rev. 36(2), 181–201 (2017).
- 23. . Vaccination uptake amongst older adults from minority ethnic backgrounds: a systematic review. PLOS Med. 18(11), e1003826 (2021).
- 24. . The role of health information technology in pneumococcal vaccination uptake among adults with heart disease. Telemedicine e-Health 28(5), 699–705 (2022).
- 25. . Factors associated with pneumococcal vaccination in 2040 people with type 2 diabetes: a cross-sectional study. Diabetes Metab. 46(2), 137–143 (2020).
- 26. . Pneumococcal vaccination coverage and uptake among adults in switzerland: a nationwide cross-sectional study of vaccination records. Front. Public Health 9, 9 (2022).
- 27. National Center for Immunization and Respiratory Diseases. ‘Pneumococcal Vaccination: Summary of Who and When to Vaccinate’ (2023). www.cdc.gov/vaccines/vpd/pneumo/hcp/who-when-to-vaccinate.html#adults-19-64
- 28. . Multiple comorbidities increase the risk of death from invasive pneumococcal disease under the age of 65 years. J. Infect. Chemother. 27(9), 1311–1318 (2021).
